Table 1b.
Clinical characteristics of the cohort of patients with PD enrolled in the study.
| Subject no. | Age years | Sex | Diagnosis | Years since diagnosis | Lateralization | H & Y score | UPDRS total score | Medication/Treatment | LEDD in mg |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 66 | M | Possible PD | 0.5 | Right | 1.5 | 23 | MAOB | 100 |
| 2 | 72 | F | Possible PD | 1.0 | Right | 1 | 11 | MAOB | 100 |
| 3 | 67 | M | Possible PD | 0.1 | Bilateral | 2 | 34 | - | 0 |
| 4 | 66 | F | Probable PD | 7.0 | Right | 1.5 | 17 | cl-dopa, DA, MAOB | 1175 |
| 5 | 52 | F | Possible PD | 2.0 | Left | 1.5 | 31 | cl-dopa, DA, MAOB | 1500 |
| 6 | 63 | M | Probable PD | 7.5 | Left | 1 | 16 | l-dopa, DA, MAOB | 740 |
| 7 | 58 | M | Probable PD | 4.0 | Right | 1.5 | 27 | cl-dopa, DA, MAOB | 460 |
| 8 | 63 | M | Possible PD | 2.5 | Bilateral | 2 | 20 | cl-dopa, DA, MAOB | 487.5 |
| 9 | 65 | F | Possible PD | 1.5 | Left | 1 | 6 | DA, MAOB | 220 |
| 10 | 69 | F | Possible PD | 0.2 | Right | 1 | 10 | MAOB | 100 |
| 11 | 52 | F | Probable PD | 8.2 | Right | 1 | 18 | cl-dopa, DA, MAOB | 325 |
M= male; F = female; H&Y= Hoehn andYahr Scale; MAOB = Monoamine Oxidase B inhibitor, cl-dopa = Carbidopa-Levodopa, DA = Dopamine Agonists; LEDD = Levodopa equivalent daily dose. Diagnosis has been defined according to Gelb’s criteria (Gelb et al., 1999).